Cancer BiologybioRxivPreprint
GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity
M. Ribeiro, N. Profitos-Peleja, J. C. Santos…·G. Roue
This study shows that TG-1801 enhances ublituximab's anti-lymphoma activity through GPR183-mediated mechanisms in B-NHL models.
DOI 10.1101/2022.03.31.486558